Senior Director, Medical Director, Lung Cancer and Early Pipeline

Jazz Pharmaceutical sis a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments.

Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit  for more information.

The Senior Director, Medical Director, Lung Cancer and Early Pipeline will be the Medical Affairs lead for the lung cancer disease area and post proof of concept (POC) pipeline products, including early assets without a defined lead indication globally. They are a key member of Global Commercialization Organization Medical Affairs (GCOMA) Oncology and report to the Executive Director, Solid Tumor Lead.

The Senior Medical Director will be the subject matter expert lead for the Solid Tumor Oncology product, partnering closely with US cross-functional partners to create and execute the US Medical Affairs strategy, including the integrated evidence generation plan. This is a strategic role with execution responsibilities and is accountable for ensuring the needs and priorities of the US region are represented and addressed through engagement with key partners across Jazz.

This role ensures a deep understanding of customer, patient, and healthcare system needs are represented consistently across cross-functional discussions and decision-making forums.

The Senior Medical Director will partner with the early/clinical development team to determine and align on future treatment landscape scenarios for assets in early development in additional therapeutic areas for early pipeline products without a lead indication and those in new oncology therapeutic areas. The Sr. Director will inform and influence clinical development strategy, evidence plans and the target product profile for such products, with a bias toward the United States therapeutic landscape as the driver of strategic planning.

The role serves as a critical interface between Medical Affairs and global R&D, Early/Clinical Development, Global Product Development and Commercialization functions, partnering closely with US colleagues to ensure regional insights and priorities are understood, communicated, and appropriately considered within the Global Product Team (GPT), Commercial Development Team (CDT), Medical Functional Matrix Team (FMT), and governance forums including the Portfolio Governance Committee (PGC) and Development Project Review Committee (DPRC).

Essential Functions/Responsibilities:

• Lead the Medical FMT for the Solid Tumor Oncology product
• Lead and develop the annual and long-range US Medical Plan for the Solid Tumor Oncology product
• Lead the development, maintenance, and execution of the Integrated Evidence Generation Plan (IEGP), including investigator-sponsored studies, real-world evidence initiatives, health outcomes research, and Phase IV interventional studies, where appropriate
• Lead the development of the scientific narrative for the Solid Tumor Oncology product by identifying and advancing key analytic needs and informing the interpretation of pivotal trial data
• Represent and advocate for medical perspectives within global cross-functional teams and governance forums, including GPT, CDT, PGC, and DPRC
• Contribute Medical Affairs expertise to inform early development activities for early pipeline assets, including Target Product Profile (TPP) development, clinical…